Thomas Dubensky on How ADU-S100 Activates STING

Thomas W. Dubensky, PhD
Published: Friday, Apr 29, 2016



Thomas W. Dubensky Jr, PhD, chief scientific officer, Aduro Biotech, discusses a study of ADU-S100 and how it activates the human STING receptor, which is found to have presence in multiple tumor types.

The live-attenuated, double-deleted Listeria mononcytogenes (LADD) technology developed by Aduro Biotech is used in pancreatic cancer as a platform to induce antigens against specific tumors, Dubensky explains. Through a research collaboration, it was found that the potency of the LADD platform is due to inducing interferon expression, which turned out to be STING dependent.

ADU-S100, a small molecule, was delivered in preclinical models of advanced tumors and was found to promote anti-tumor efficacy. However, by activating the STING pathway in the tumor microenviornment, the tumor-resident dendritic cells could present antigen, produce a T-cell response, and was found to be systemically active.


Thomas W. Dubensky Jr, PhD, chief scientific officer, Aduro Biotech, discusses a study of ADU-S100 and how it activates the human STING receptor, which is found to have presence in multiple tumor types.

The live-attenuated, double-deleted Listeria mononcytogenes (LADD) technology developed by Aduro Biotech is used in pancreatic cancer as a platform to induce antigens against specific tumors, Dubensky explains. Through a research collaboration, it was found that the potency of the LADD platform is due to inducing interferon expression, which turned out to be STING dependent.

ADU-S100, a small molecule, was delivered in preclinical models of advanced tumors and was found to promote anti-tumor efficacy. However, by activating the STING pathway in the tumor microenviornment, the tumor-resident dendritic cells could present antigen, produce a T-cell response, and was found to be systemically active.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x